1 ,3-dione) to give respective JV-enamine derivatives of 1. One of these derivatives iV-(l-carboethoxypropen-l-yl-2)daunorubicin (3) exhibits reduced subacute toxicity and cardiotoxicity with retention of antileukemic activity6>7). It has been calculated1, that in these JV-enamine derivatives of 1 the basicity of the 3'-ammo function is retained making it possible to bind to DNA.That led us to obtain a series of other enamine derivatives of anthracyclines with different lipophilic properties and varying degree of steric bulk as well as basicity of the 3'-amino group (see Fig. 1 ). In compounds 5 and 6 the carboethoxy group in the enamine part of 3 was replaced by a carbomethoxy and carbo-terr-butoxy group, respectively, compounds 10 and ll contain an additional carboalkoxy group instead of the methyl group. Compound9 is an analogue of the earlier obtained 75) with a phenyl group instead of the methyl group at the carbonyl function. Compounds12 and 13 have the l-(2-diethoxycarbonyl)-Dr. A. Tempczyk, University of Gdansk, private information. FEB. 1988 vinyl-and l-(2-cyano-2-ethoxy)vinyl-substituent at the S'-amino group, respectively. It was stated, that the cardiotoxic and mutagenic side effects of 1 appear to be greatly reduced in the 5-imino-derivative8).
Therefore we have prepared also 5-imino-iV-(l-carboethoxypropen-l-yl-2)-and 5-imino-iV-(penten-2-one-4-yl-2)daunorubicin, as 5-imino-derivatives of 3 and 7, respectively.
To synthesize various JV-enamine derivatives of 1 and 2 (see Fig. 1 ; 3~13) the respective antibiotics were reacted with an excess of^-diketones, alkyl acetylenedicarboxylates, acetoacetic esters, ethoxymethylenemalonate and/or ethoxymethylenecyanoacetate. To obtain the compounds14 and 15 (see Fig. 1 ) 5-iminodaunorubicin was used as substrate. All reactions took place in mild conditions. TLC of the crude products indicated only traces of impurities, however if alkyl acetylenedicarboxylates were used as reaction reagents corresponding products 10 and ll were obtained in admixture with other unidentified derivatives of 1. The obtained iV-enamine derivatives 3~15 were purified by meansof columnchromatographyon molecular sieves or silica gel and the yields were in the range 45 to 70%with the exception of 4 that was obtained in 35%yield. The structures proposed for compounds 3~15 were demonstrated by their spectral data (UV-visible, IR and XHNMR)as well as their MS determination (field desorption (FD) technique) and elemental analysis data (see Table 1 ). The electronic absorption spectra in the visible region were identical with that of the parent compounds; the IR spectra showed in the 1725~1580 cm"1 region several strong bands characteristic for free and chelated carbonyl groups; the IR spectrum of 13 indicated additionally the C=Nband at 2220
cm""1. It was considered on the basis of UV, IR and XHNMRspectra analysis, that simple enamine derivatives of glycosylamines are intramolecularly bonded, /S-amino-o^-unsaturated ketones9~n) (Fig. 2) . Similar structures of chelated iV-enamine derivatives 3~15 were deduced from the XHNMRspectra (the position of NH signals at very low fields <5 8~ll).
In the reaction of 1 with ethyl ethoxymethylene cyanoacetate we have obtained two major products. One of them was isolated in pure form by means of column chromatography on silica gel. Its *HNMRspectrum showed the signal at d 7.93 assigned to the amino proton NH. The remaining was isolated again as mixture of both compounds in similar proportions. Its XHNMRspectrum besides the signal at d 7.93 revealed another one at d 5.38 due to the -CH(p roton. On the basis of these data and MS determination (identical mass ions) we concluded that the synthesized derivative appears in two tautomeric forms as Scheme1. The reaction between a primary amine and an unsymmetrical /3-dicarbonyl compound can, in principle, give rise to two isomeric enamines (structure c or d). It has been well established for condensates of benzoylacetaldehyde and/or l-phenyl-l,3-butanedione with 2-amino-2-deoxyglucose, that these substances react with the carbonyl group of benzoylacetaldehyde and 1-phenyl-1,3-butanedione which is further away from the phenyl group (structure c12)). XHNMRspectrum of the enamine part of the condensation product of 1 with l-phenyl-1,3-butanedione (compound 9) is similar with that of 2-deoxy-2-[2-(4-oxo-4-phenyl-2-butenyl)amino]-Dglucose9). It allowed us to propose the structure of compound 9 as in Fig. 1 . Wehave observed also, that in the reaction of dibenzoylmethane with 1 performed in the same and more drastic conditions, as we have used in the reaction of 1-phenyl-1,3-butanedione with 1 no enamine products were formed. This is an additional argument for the structure indicated in Fig. 1 .
Biological Activity and Discussion
The synthesized JV-enamine derivatives of 1, 2 and of 5-iminodaunorubicin were tested for the growth inhibition of L1210 cells in vitro and against P388 leukemia in vivo. It has been found that all the examined compoundsexhibit cytotoxicity in vitro of about one order of magnitude lower than the parent antibiotics. The in vivo activity of the daunorubicin derivatives 5, 6 and 9~ll was comparable with that of 1 (T/C 130% at the dose 25 mg/kg) whereas 12 and 13 were less active (T/C -100% at the same level dose). Doxorubicin derivative 4 has shown lower activity than doxorubicin (2) itself, and 8 approaches the activity of 2 (T/C 160% at the dose 12.5 mg/kg). These preliminary data demonstrated that structural changes in the enamine part of the synthesized JV-enamine derivatives of 1 and 2 does not cause essential changes in antileukemic activity. Howeverthe examined compounds appear to be less toxic than the parent drugs6>7). The comparison of in vivo antitumor activity and toxicity of the series of iV-enamine derivatives of 1 synthesized with the data obtained for previously described compounds of this group5~7) indicate that the optimal activity is shown by iV-(l-carboethoxypropen-l-yl-2)daunorubicin (3). iV-Enamine derivatives of 5-iminodaunorubicin (14 and 15) are less active than their daunorubicin analogues (3 and 7). It was disappointing because 5-iminodaunorubicin demonstrated antileukemic activity similar with that of 18).
Exp er imental Instrumental Analysis
MPwas determined with a Kofler hot plate apparatus and are uncorrected. IR spectra were recorded on a UR-10Zeiss Spectrometer in KBrpellets. XHNMRspectra were recorded on a Varian 90 MHzspectrometer using TMSas internal standard and are reported as ppm. Splitting patterns are designed as: s; singlet, d; doublet, t; triplet, m; multiplet. A Beckmanspectrometer was used for UVspectral determinations. MWwas determined by mass spectrometry (FD technique) on a Varian Mat 711 instrument. The instrumental conditions were the following; wire heating current 5-20 mA, ion source temp 70~100°C, accelerating voltage 4~6 kV. Column chromatography was performed on Silica gel 60 (70-230 mesh, Merck) and on molecular sieves Sephadex LH-20.
Synthesis
General Procedure: A sample of 1 mmol of daunorubicin, doxorubicin or 5-iminodaunorubicin (as free base) in 50 ml of a mixture of CHC13-MeOH(10 : 1) was stirred with a 2-3-equivalents of the appropriate reagent except for the synthesis of compounds6 and 12 where a 6-molar excess was necessary. The reaction was carried out under nitrogen in roomtemp or 40°C. The reaction times carried from 1 hour (compounds 10 and ll), 3-5 hours (compounds 5, 9 and 12-15) to 10 hours (compounds 3, 4, 6 and 7). After evaporation of the reaction mixture (in vacuo) to a small volume the crude product was isolated by precipitation with petroleum ether and purified by means of column chromatography using molecular sieves (Sephadex LH-20) or silica gel. However the application of the last column packing caused loss of yields about 15 % (compound 6 could be purified only by means of molecular sieves because of its instability). The following solvent systems were used for following compounds: 10 and ll, CHC13-acetone (7:1); 12 and 13, benzene-acetone (4 :1); 14, benzeneacetone (2 : 1); 15, CHC13 -MeOH (30: 1). Compounds 3-9 were purified on molecular sieves (Sephadex LH-20; solvent system, CHC13 -MeOH (2 : 1)).
Biological Activity: The antitumor activity in vitro was expressed as the concentration of compound required to inhibit by 50% the growth of L1210 leukemia cells (ED50). ED50values were estimated 48 hours after incubation of L1210 cells with the tested compounds in RPMI1640 medium supplemented with 5%fetal calf serum13). In vivo data are the results of screening performed under the Developmental Therapeutics Program, Division of Cancer Treatment, National Cancer Institute, Bethesda, Maryland, U.S.A.
CDFmice were injected ip with 106 P388 lymphocytic leukemia cells on day 0 and treated ip on days 5, 9 and 13 with drug dose specified. T/C is the ratio of medium survival time expressed as percent of untreated controls.
